Incivek and Victrelis to Kick-Start Huge Hepatitis C Market Growth
The approval of the US Food and Drug Administration in May of last year for two drugs, Incivek and Victrelis, has sparked explosive pharmaceutical industry revenue gains that will see the hepatitis C market grow exponentially in size by 2018, predicts new research by healthcare sector analysts GBI Research.
The firm's latest report* states that the market for hepatitis C will climb from a 2011 value of $2.6 billion to just under $15 billion by the end of 2018, at a Compound Annual Growth Rate (CAGR) of 28%.
According to GBI Research, last year's introduction of Incivek (co-developed by Vertex and Johnson & Johnson) and Victrelis (from US firm, Merck & Co.) marked the beginning of a boom period for the global hepatitis C market following years of sliding revenues.
Both of these highly influential treatments will be subject to large-scale marketing across the US, Europe and Japan in the coming years and will contribute significantly to the industry's value.
Drug manufacturer profits are expected to be further bolstered by the imminent launch of oral DAA molecules (the first of which should be on the market in 2015) and the increased reliance on prescribing DAA drug combinations within the healthcare community.
Almost 8 million people worldwide were estimated to have chronic hepatitis C virus (HCV) in 2011, climbing from 7.6 million in 2004. Thanks to improving treatments and an increasing awareness within the general population, GBI Research expects this figure to drop below the 7 million mark by 2018.
Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy
This report provides insights into the global hepatitis C therapeutics market up to 2018.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
Abstract
Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy
Summary
GBI Research, the leading business intelligence provider, has released its latest research "Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy", which provides insights into the global hepatitis C therapeutics market up to 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report examines the global hepatitis C treatment usage patterns, and the geographical distribution of hepatitis C therapeutics and markets across the US, the top five countries of Europe and Japan. The report also includes insights into the hepatitis C therapeutics R&D product pipeline and explores the competitive landscape, including major players in the hepatitis C therapeutics market. Finally, the report also includes analysis of the Mergers and Acquisitions (M&As) and licensing agreements that took place in the hepatitis C therapeutics market from 2010 to 2012.
In 2011, the hepatitis C therapeutics market was estimated at $2.6 billion. From 2004 to 2011, the market grew at the CAGR of 2.7%, with the launch of Incivek and Victrelis in 2011 boosting positive growth. The market had seen a significant decline in value due to the low uptake of Pegylated Interferon (PI) therapies and subsequent patient warehousing in anticipation of more effective drugs being launched. The launch of the two PIs added a billion dollars to the market in 2011 and helped to achieve a positive CAGR. GBI Research analyses estimate that the hepatitis C therapeutics market in the top seven markets will be valued at $14.9 billion in 2018, with a CAGR of 28.3% over the forecast period. These estimates are based on the continued adoption of PIs as the gold standard treatment option for hepatitis C, and the imminent launch of oral DAA molecules, the first of which should be in the market in 2015. Further, combinations of DAA drugs will improve the overall effectiveness of treatment and will have less side-effects than PIs. This should result in a significant increase in diagnosis and treatment rates over the forecast period.
Scope
Data and analysis on the hepatitis C therapeutics market in the leading geographies of the world - the US, Japan, the UK, Germany, France, Italy and Spain.
Annualized market data for the hepatitis C therapeutics market from 2004 to 2011, with forecasts to 2018.
Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
Key drivers and restraints that have had a significant impact on the market.
The competitive landscape of the global hepatitis C therapeutics market including top companies benchmarking. The key companies studied in this report are Vertex Pharmaceuticals, Inc., Merck & Co., Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company (BMS), Abbott Laboratories, F. Hoffmann-La Roche Ltd., Johnson & Johnson / Tibotec BVBA, Boehringer Ingelheim GmbH, Novartis AG, Achillion Pharmaceuticals, Inc., and Idenix Pharmaceuticals, Inc.
Key M&A activities and licensing agreements that took place in the years 2010 to 2012 in the hepatitis C therapeutics market.
Reasons to buy
Align their product portfolios to markets with high growth potential.
Build effective strategies to launch their pipeline products by identifying potential geographies.
Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
Develop key strategic initiatives by studying the key strategies of top competitors.
Devise a more tailored strategy through the understanding of key drivers and barriers and market potential of each indication.
Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
Table of Contents
TOC
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 10
3 Market Overview 11
3.1 Introduction 11
3.1.1 HCV Classification 11
3.1.2 HCV Genome 12
3.1.3 HCV Diagnosis 13
3.1.4 HCV Treatment Goals 13
3.1.5 Current HCV Treatment Options 15
3.1.6 Future HCV Treatment Paradigm 16
3.2 Global Hepatitis C Therapeutics Market 18
3.2.1 Revenue 18
3.2.2 Annual Cost of Therapy 22
3.2.3 Treatment Usage Pattern 23
3.2.4 Market Trends 26
4 Geographic Landscape 27
4.1 The US 27
4.1.1 Revenue 27
4.1.2 Annual Cost of Therapy 28
4.1.3 Treatment Usage Pattern 29
4.2 Top Five Countries of Europe 31
4.2.1 Revenue 31
4.2.2 Revenue by Country 33
4.2.3 Annual Cost of Therapy 35
4.2.4 Treatment Usage Pattern 36
4.3 Japan 38
4.3.1 Revenue 38
4.3.2 Annual Cost of Therapy 39
4.3.3 Treatment Usage Pattern 40
4.4 Other Markets 42
4.4.1 Australia 42
4.4.2 China 46
4.4.3 India 49
5 Pipeline Analysis 52
5.1 Research and Development Pipeline 52
5.2 Highlights from the International Liver Congress 2012, European Association for the Study of the Liver 53
5.3 Recently Launched 55
5.3.1 Incivek/Telavic/Incivo (telaprevir) 55
5.3.2 Victrelis 58
5.3.3 Perspective on Incivek and Victrelis 59
5.4 Most Promising Molecules in Phase III 61
5.4.1 GS-7977 61
5.4.2 BMS-790052 (daclatasvir) 67
5.4.3 TMC-435 68
5.4.4 BI-201335 70
5.5 Most Promising Molecules in Phase II 73
5.5.1 ABT-450 73
5.5.2 GS-5885 74
5.5.3 RG7128 (mericitabine) 74
5.5.4 ACH-1625 75
5.6 Combination Therapy Development 76
5.6.1 With PEG-IFN and RBV 76
5.6.2 With RBV only 77
5.6.3 Without PEG-IFN and RBV 78
6 Competitive Landscape 80
6.1 Market Share Analysis 80
6.2 Competitive Profiling 81
6.2.1 Vertex Pharmaceuticals, Inc. 81
6.2.2 Merck & Co., Inc. 82
6.2.3 Gilead Sciences, Inc. 84
6.2.4 Bristol-Myers Squibb Company 85
6.2.5 Abbott Laboratories 87
6.2.6 F. Hoffmann-La Roche Ltd. 88
6.2.7 Johnson & Johnson/Tibotec BVBA 89
6.2.8 Boehringer Ingelheim GmbH 91
6.2.9 Novartis AG 92
6.2.10 Achillion Pharmaceuticals, Inc. 93
6.2.11 Idenix Pharmaceuticals, Inc. 94
7 Strategic Consolidations 95
7.1 Deals by Year 96
7.2 Deals by Type 97
7.3 Deals by Value 98
7.4 Deals by Region 99
7.5 Mergers and Acquisitions 100
7.5.1 Major M&A Deals 101
7.6 Licensing Agreements 102
7.6.1 Major Licensing Agreements 103
7.7 Partnerships 104
7.7.1 Major Partnership Deals 105
8 Appendix 106
8.1 Market Definitions 106
8.2 Abbreviations 106
8.3 Bibliography 107
8.4 Research Methodology 108
8.4.1 Coverage 108
8.4.2 Secondary Research 109
8.4.3 Primary Research 109
8.4.4 Therapeutic Landscape 110
8.4.5 Market Size by Geography 112
8.4.6 Geographical Landscape 113
8.4.7 Pipeline Analysis 113
8.4.8 Competitive Landscape 113
8.4.9 Expert Panel Validation 113
8.5 Contact Us 113
8.6 Disclaimer 113
List of Tables
1.1 List of Tables
Table 1: Characteristics of HCV Genotypes 1-3 12
Table 2: Functions of HCV Proteins and Therapeutic Approach 12
Table 3: Clinical Endpoints for HCV Therapy 14
Table 4: Patient Classification Based on Viral Response to Therapy 14
Table 5: Direct-acting Antiviral Therapies in Development 16
Table 6: Host-Targeting Antiviral Therapies in Development 17
Figure 46: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Deals by Year, 2010-2012 96
Figure 47: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Deals by Type, 2010-2012 97
Figure 48: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Deals by Value, 2010-2012 98
Figure 49: Hepatitis C Therapeutics Market, Global, Strategic Consolidations, Deals by Region, 2010-2012 99
Figure 50: GBI Research Market Forecasting Model 112
Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy published by GBI Research in October 15, 2012. This report consists of Pages: 113 and the price starts from US $ 3500.
Press Release
Global Market for Hepatitis C to Reach Nearly $15 Billion in 2018
October 26th, 2012
Global Information Inc. would like to present a new market research report, "Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy" by GBI Research.
The approval of the US Food and Drug Administration in May of last year for two drugs, Incivek and Victrelis, has sparked explosive pharmaceutical industry revenue gains that will see the hepatitis C market grow exponentially in size by 2018, predicts new research by healthcare sector analysts GBI Research.
The firms latest report, " Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy ", states that the market for hepatitis C will climb from a 2011 value of $2.6 billion to just under $15 billion by the end of 2018, at a Compound Annual Growth Rate (CAGR) of 28%.
According to GBI Research, last years introduction of Incivek (co-developed by Vertex and Johnson & Johnson) and Victrelis (from US firm, Merck & Co.) marked the beginning of a boom period for the global hepatitis C market following years of sliding revenues . Both of these highly influential treatments will be subject to large-scale marketing across the US, Europe and Japan in the coming years and will contribute significantly to the industrys value.
Drug manufacturer profits are expected to be further bolstered by the imminent launch of oral DAA molecules (the first of which should be on the market in 2015) and the increased reliance on prescribing DAA drug combinations within the healthcare community. Almost 8 million people worldwide were estimated to have chronic hepatitis C virus (HCV) in 2011, climbing from 7.6 million in 2004. Thanks to improving treatments and an increasing awareness within the general population, GBI Research expects this figure to drop below the 7 million mark by 2018.
